BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (Nasdaq:TRCA) today announced that the Company has completed enrollment of all patients in its MS301 Phase IIIb trial, a study evaluating the efficacy and safety of the current formulation of Increlex® (mecasermin [rDNA origin] injection) administered in children with Primary IGFD. Increlex® is currently approved in the United States for the treatment of severe Primary IGFD.
